April 2012 Drug Information Update - Pharmacy Benefits ...

More documents

Recommendations

Info

• Bedford discontinued lorazepam in May, 2011 to concentrate on the manufacturing of other products. • West-Ward acquired Baxter’s lorazepam injection products in May, 2011. The company cannot provide a reason for the shortage. • Hospira states lorazepam vials are on shortage due to increased demand. The 1 mL iSecure syringes were discontinued in September 2011 • Akorn has increased production to help meet demand. Article link: http://www.ashp.org/DrugShortages/Current/Bulletin.aspx?id=747 Source: www.ashp.org Echothiophate Powder for Ophthalmic Solution March 30, 2012 Products Affected - Description Phospholine Iodide 0.125%, Pfizer 5 mL bottle (NDC 00046-1065-05) Reason for the Shortage • Pfizer (formerly Wyeth) states Phospholine Iodide is in short supply due to a raw material shortage. Article link: http://www.ashp.org/DrugShortages/Current/Bulletin.aspx?id=85 Source: www.ashp.org Ceftazidime Injection March 30, 2012 Products Affected - Description Ceftazidime vials Ceftazidime injection, Pfizer 500 mg vials (NDC 00069-0013-01) - discontinued 1 gm vials (NDC 00069-0011-01) - discontinued 2 gm vials (NDC 00069-0012-01) - discontinued 6 gm vials (NDC 00069-0014-01) - discontinued Ceftazidime injection, Sagent 1 gm vials, packages of 25 (NDC 25021-0127-20) 2 gm vials, packages of 10 (NDC 25021-0128-50) 6 gm vials, packages of 6 (NDC 25021-0129-99) Ceftazidime injection, West-Ward 1 gm vials, packages of 25 (NDC 10019-0691-02) - discontinued 2 gm vials, packages of 10 (NDC 10019-0692-03) - discontinued 6 gm vials, packages 6 (NDC 10019-0693-04) - discontinued Tazicef injection, Hospira 1 gm ADD-Vantage vials, packages of 25 (NDC 00409-5092-16) 1 gm Novaplus ADD-Vantage vials, packages of 25 (NDC 00409-5092-52) 2 gm ADD-Vantage vials, packages of 10 (NDC 00409-5093-11) 2 gm Novaplus ADD-Vantage vials, packages of 10 (NDC 00409-5093-51) Reason for the Shortage • Pfizer discontinued all of its ceftazidime injection products in late-November, 2011. • West-Ward discontinued all of its ceftazidime injection products in January 2012. • Hospira has ceftazidime on shortage due to manufacturing delays. • Sagent was not able to provide a reason for the shortage. 78
• Covis purchased all rights to Fortaz from GlaxoSmithKline. Article link: http://www.ashp.org/DrugShortages/Current/Bulletin.aspx?id=869 Source: www.ashp.org Calcium Acetate Capsules March 30, 2012 Products Affected - Description Calcium acetate capsules, Roxane 667 mg capsules, 200 count (NDC 00054-0088-26) PhosLo capsules, Fresenius 667 mg capsules, 200 count (NDC 49230-0640-21) Reason for the Shortage • Roxane and Fresenius cannot provide a reason for the shortage. Article link: http://www.ashp.org/DrugShortages/Current/Bulletin.aspx?id=819 Source: www.ashp.org 79
Page 1 and 2:
April 2012 Drug Information Update
Page 3 and 4:
First-Time Generics GENERIC DRUG NA
Page 5 and 6:
GENERAL ANESTHETICS, INJECTABLE MID
Page 7 and 8:
Gruenhaupt, Mark R.Ph. Argus Health
Page 9 and 10:
Statin Drugs - Drug Safety Communic
Page 11 and 12:
Vytorin (ezetimibe/simvastatin) Tab
Page 13 and 14:
low blood sugar (hypoglycemia) in p
Page 15 and 16:
Some women with depression who beco
Page 17 and 18:
Survival increased for all groups o
Page 19 and 20:
finding that it also may reduce the
Page 21 and 22:
Syringes (2 mL size), Rx only. NDC
Page 23 and 24:
Patheon Pharmaceuticals Inc., Cinci
Page 25 and 26:
50-ct. bottles (NDC 0067-6238-50);
Page 27 and 28: PRODUCT (Class II) 1) Ventolin HFA
Page 29 and 30: Lot #: 0693, Exp: 10/2012 RECALLING
Page 31 and 32: 24 (Display case UPC# 3030045074923
Page 33 and 34: CODE Lot # 139961 RECALLING FIRM/MA
Page 35 and 36: Reason for the Shortage • Teva co
Page 37 and 38: Reason for the Shortage • Ben Ven
Page 39 and 40: Products Affected - Description Gan
Page 41 and 42: 37.5 mg/25 mg, 1000 count (NDC 0078
Page 43 and 44: Acyclovir tablets, Major 400 tablet
Page 45 and 46: 500 mg, 100 count (NDC 63304-0726-0
Page 47 and 48: 750 mg tablets, 100 count (NDC 1013
Page 49 and 50: • Bedford Laboratories has multip
Page 51 and 52: Daunorubicin Hydrochloride Injectio
Page 53 and 54: Ciprofloxacin Immediate-Release Tab
Page 55 and 56: • APP had tobramycin 40 mg/mL pre
Page 57 and 58: • Ben Venue voluntarily suspended
Page 59 and 60: 50 mg/mL, 10 mL vial, package of 10
Page 61 and 62: 2 mL vial, preservative-free (NDC 6
Page 63 and 64: 5 mg single dose vial, package of 1
Page 65 and 66: 20 mL glass ampule, sterile pack (N
Page 67 and 68: 2 mL iSecure syringe (NDC 00406-112
Page 69 and 70: Lidocaine 0.5% Xylocaine 0.5% injec
Page 71 and 72: • Teva discontinued all ciproflox
Page 73 and 74: Nicardipine hydrochloride injection
Page 75 and 76: Article link: http://www.ashp.org/D
Page 77: • Apotex had metformin products u
show all

April 2012 Drug Information Update - Pharmacy Benefits ...

Create successful ePaper yourself

Delete template?

Save as template?